Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer

This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 / PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolled across approximately 70 sites from North America, Europe and Asia.
Not Available
Phase II
Adults
Not Available
Not Available
Davis, Nancy
International
Vanderbilt University
03-01-2019
Treatment
VICCURO18120
NCT03547973

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Patients with histologically confirmed urothelial cancer.

ECOG Performance status score of 0 or 1.

Cohort 1: Have had progression or recurrence of urothelial cancer following receipt of platinum-containing regimen (cisplatin or carboplatin):

Received a first-line platinum-containing regimen in the metastatic setting or for inoperable locally advanced disease;

Or received neo/adjuvant platinum-containing therapy for localized muscle-invasive urothelial cancer, with recurrence/progression ?12 months following completion of therapy.

Cohort 1: In addition to above criterion, have had progression or recurrence of urothelial cancer following receipt of an anti-PD-1 /PD-L1 therapy.

Cohort 2: Were ineligible for platinum-based therapy for first line metastatic disease and have had progression or recurrence of urothelial cancer after a first-line therapy for metastatic disease with anti-PD-1/PD-L1 therapy. Subject may not have received any platinum for treatment of recurrent, metastatic or advanced disease.

Adequate renal and hepatic function.

Adequate hematologic parameters without transfusional support.

Creatinine clearance ?30mL/min as calculated by the Cockroft-Gault formula.

Subjects must have a 3-month life expectancy.

Have measurable disease by CT or MRI as per RECIST 1.1 criteria.



Exclusion Criteria:

Women who are pregnant or lactating.

Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.

Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events due to a previously administered agent.

Requires concomitant medication interfering with ABCA1 transporter or UGT1A1

Has an active second malignancy.

Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

Has known active Hepatitis B or Hepatitis C

Has other concurrent medical or psychiatric conditions

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: